Application of next-generation sequencing to detect MTB resistance to first- and second-line anti-TB drugs

Panova, Anna; Vinokurov, Anatoliy; Lagutkin, Denis; Gracheva, Alexandra; Николаев, А. Н.; Samoilova, Anastasia; Vasilyeva, Irina

doi:10.1183/13993003.congress-2020.1605

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sensitivity to ethambutol and kanamycin was lower (87.5% and 88.9%). Sensitivity to amikacin and capreomycin was similar (60.0%), and the lowest sensitivity was observed with PZA (29.4%), while specificity was over 90% for all anti-tuberculosis drugs [119].…”

Section: Next-generation Sequencing (Ngs)mentioning

confidence: 85%

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

Naidoo,

Perumal,

Ngema

et al. 2023

Pathogens

View full text Add to dashboard Cite

Global tuberculosis (TB) eradication is undermined by increasing prevalence of emerging resistance to available drugs, fuelling ongoing demand for more complex diagnostic and treatment strategies. Early detection of TB drug resistance coupled with therapeutic decision making guided by rapid characterisation of pre-treatment and treatment emergent resistance remains the most effective strategy for averting Drug-Resistant TB (DR-TB) transmission, reducing DR-TB associated mortality, and improving patient outcomes. Solid- and liquid-based mycobacterial culture methods remain the gold standard for Mycobacterium tuberculosis (MTB) detection and drug susceptibility testing (DST). Unfortunately, delays to result return, and associated technical challenges from requirements for specialised resource and capacity, have limited DST use and availability in many high TB burden resource-limited countries. There is increasing availability of a variety of rapid nucleic acid-based diagnostic assays with adequate sensitivity and specificity to detect gene mutations associated with resistance to one or more drugs. While a few of these assays produce comprehensive calls for resistance to several first- and second-line drugs, there is still no endorsed genotypic drug susceptibility test assay for bedaquiline, pretomanid, and delamanid. The global implementation of regimens comprising these novel drugs in the absence of rapid phenotypic drug resistance profiling has generated a new set of diagnostic challenges and heralded a return to culture-based phenotypic DST. In this review, we describe the available tools for rapid diagnosis of drug-resistant tuberculosis and discuss the associated opportunities and challenges.

show abstract

Section: Next-generation Sequencing (Ngs)mentioning

confidence: 85%

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

Naidoo,

Perumal,

Ngema

et al. 2023

Pathogens

View full text Add to dashboard Cite

show abstract

“…Low sensitivity was observed for pyrazinamide (29.4%), amikacin and capreomycin (60.0%). Specificity was more than 90% for all anti-TB drugs [64].…”

Section: E-poster Sessions: Tuberculosis and Society Non-tuberculousmentioning

confidence: 92%

“…P anova et al [ 63 ] studied an application of next-generation sequencing (NGS) to detect M. tuberculosis resistance to first- and second-line anti-tuberculosis drugs aiming to find key drug resistance-associated mutations of M. tuberculosis and compare it with phenotype-based methods. Drug resistance was evaluated through single nucleotide polymorphisms identification in resistance-associated genes ( rpsL , rRNA , katG , inhA , rpoB , embB , pncA , rpsA , gyrA , gyrB , rrs , eis ).…”

Section: E-poster Sessions: Tuberculosis and Society Non-tuberculous Mycobacteria And Latent Tuberculosis Infection The Young The Old Andmentioning

confidence: 99%

ERS International Congress 2020: highlights from the Respiratory Infections assembly

et al. 2021

View full text Add to dashboard Cite

In the COVID-19 pandemic year 2020, the 30th edition of the ERS Congress took place for the first time in a fully virtual format. Despite the challenging nature of the task to create and deliver an online event of this size and scope, the ERS Congress 2020 turned to be a great success, welcoming over 33 000 delegates to the specially designed online platform and offering more than 450 scientific and educational sessions. Somewhat predictable, this year's Congress dedicated a full day on COVID-19 topic, highlighting that infection with SARS-CoV-2 is a respiratory disease. In this article the Early Career Members of the Assembly 10 (Respiratory Infections and Tuberculosis) review some of the most interesting sessions including presentations and posters on respiratory infections and tuberculosis that were deemed as important.

show abstract

Application of next-generation sequencing to detect MTB resistance to first- and second-line anti-TB drugs

Cited by 2 publications

References 0 publications

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

ERS International Congress 2020: highlights from the Respiratory Infections assembly

Contact Info

Product

Resources

About